eMedicine Specialties > Pediatrics: General Medicine > Parasitology

Neurocysticercosis

Author: Vinod K Dhawan, MD, FACP, FRCP(C), Professor, Department of Clinical Medicine, University of California at Los Angeles; Professor of Medicine, Charles R Drew University of Medicine and Science; Chief, Division of Infectious Diseases, MLK-Harbor Hospital
Coauthor(s): Eric HW Kossoff, MD, Assistant Professor, Departments of Pediatrics and Neurology, Associate Director of Pediatric Neurology Residency Program, Johns Hopkins School of Medicine
Contributor Information and Disclosures

Updated: Sep 12, 2007

Introduction

Background

Neurocysticercosis is the most common parasitic infection of the CNS. Tissue-invading larval forms of the pork tapeworm Taenia solium cause the disease. Historically, neurocysticercosis was endemic to only Latin America, Asia, and Africa, although it has become increasingly frequent in the United States since the 1980s. Because of this epidemiologic change, all general pediatricians should become familiar with this disease process.

Pathophysiology

The larvae of T solium (Cysticercus cellulosae) cause neurocysticercosis. This pork tapeworm can vary in size but is notable for a scolex (head) with approximately 25 hooklets, 4 suckers, and a body with 700-1000 proglottids. The ova of the tapeworm are spread via the fecal-oral route and are approximately 40 microns in diameter with a radially striated shell. The intermediate host is the pig, which harbors the larvae after eating ova, while the definitive host is the human being.

If pig products infected with larvae are ingested, a tapeworm infection in the intestines ensues; however, if ova are ingested, neurocysticercosis may occur in this normally intermediate host. The ingested ova develop into larvae (cysticerci) and lodge in soft tissues, especially skin, muscle, and brain. Cysticerci are fluid-filled oval cysts, approximately 1-2 cm in diameter, with an internal scolex.

The eggs are found in human feces because humans are the only definitive hosts. Greatest risk for infection occurs in regions where plants in gardens or farms are fertilized with human feces and humans are exposed to contaminated soil.

In the CNS, T solium is deposited in the cerebral parenchyma, meninges, spinal cord, and eyes. Unless large numbers of cysts are present, the body's immune system does not act to destroy the organism, and cysts can live for many years undetected. A live cyst can go undetected for as long as 5 years before dying or causing symptoms in the host.

Neurologic symptoms arise when the encysted worm dies and the human mounts an associated inflammatory response. If the cyst lodges in the ventricular system (especially the fourth ventricle), hydrocephalus can occur.

Frequency

United States

Neurocysticercosis is more common among immigrants from endemic areas or children in contact with these immigrants. Several studies report approximately 1000 cases annually in adults and children. One study reported neurocysticercosis as the cause of 2% of the neurologic and neurosurgical admissions in southern California.1 With increasing immigration from Mexico and other endemic areas, incidence in the southern United States has been increasing. In a recent meta-analysis of the US medical literature, 1494 cases have been reported from 1980-2004.2

International

Neurocysticercosis is highly endemic in Latin America, Mexico, Eastern Europe, Asia, Africa, and Spain. The estimated serologic prevalence in Mexican adults is 3.6%, with positive confirmation by autopsy in 1.9%. Approximately 50 million people worldwide are infected.

Mortality/Morbidity

  • Neurocysticercosis is typically benign, and most lesions spontaneously resolve within 2-3 months; however, mortality is highly dependent on whether the disease process is simple or complicated.
  • Simple neurocysticercosis occurs in children with only a single exposure to cysts. These children tend to have solitary cysts and fewer complications. Often, children can be treated symptomatically and have a favorable prognosis. This type of neurocysticercosis tends to be observed in the United States and other nonendemic areas.
  • Complicated neurocysticercosis occurs in children in endemic areas who are repeatedly exposed to ova. Because of complications from increased intracranial pressure and difficulty controlling seizures, these children may have a less favorable prognosis. Complications can arise from uncontrolled seizures, hydrocephalus, papilledema, and occasionally, headaches and emesis, although all of these complications are rare.

Race

Neurocysticercosis tends to be diagnosed more frequently in Hispanics because of the prevalence of the organism in the countries of origin, rather than an innate property of the host child.

Sex

No sexual predilection has been noted.

Age

Reports of cysticercosis are unlikely in children younger than 2 years because of the prolonged incubation period of T solium. Most often, the disease is recognized in children older than 7 years because of this incubation period.

Clinical

History

  • The most characteristic feature in children is the acute onset of focal seizures.
    • Approximately 65-80% of children diagnosed with neurocysticercosis present with seizures, most often focal in nature.
    • Often, these children are brought to medical attention within 2 days of their initial seizure.
    • In many countries where T solium is endemic, cysticercosis is the major cause of epilepsy.
  • Increased intracranial pressure (due to hydrocephalus, which can occur in 15-25% of cases) causes other common clinical symptoms, including headache, nausea, and vomiting.
  • Less common presentations include hemiparesis, visual changes, progressive obtundation, sciatica (from cauda equina involvement), and sensory disturbances.
  • In a 1996 study by Rosenfeld et al of 753 children in Chicago, none presented with fever.3
  • Risk factors include the following:
    • Children who present with neurocysticercosis frequently have emigrated from an endemic area or are children of emigrants from such an area. In the past, many children were exposed to infection through Hispanic food handlers, but this occurrence is less common now.
    • Neurocysticercosis is endemic in certain communities because of poor sanitation, use of sewage for fertilizer, and lack of controlled pens for pigs.
    • If neurocysticercosis is a possible diagnosis in a child without such risk factors, question the family as to household contacts who have traveled to an endemic area. Remember that infection can precede symptoms by as much as 5 years.

Physical

  • Most children with neurocysticercosis have normal findings on physical and neurologic examinations.
  • Some patients may present with hemiparesis due to either a cyst or Todd paralysis after a focal seizure.
  • Rarely, children may present with papilledema, hemiparesis, sensory disturbances, or palpable subdermal cysts.

Causes

  • Larvae (cysticercus) of the tapeworm T solium cause neurocysticercosis. Larvae are acquired by ingestion of T solium ova, found in the feces of humans infected with the pork tapeworm.
  • The disease is most common in the Developing World, especially in environments where sanitation is poor. Such environments exist in rural areas of Latin America, Asia, Africa, Spain, and Eastern Europe.
  • Since the 1980s, this disease has been recognized more commonly in the United States, frequently in the states of California and Texas and in the city of Chicago, where Hispanics make up a large proportion of the community. The emergence of CT scanning and MRI studies as diagnostic tools also probably accounts for the increased detection since the 1980s.

More on Neurocysticercosis

Overview: Neurocysticercosis
Differential Diagnoses & Workup: Neurocysticercosis
Treatment & Medication: Neurocysticercosis
Follow-up: Neurocysticercosis
Multimedia: Neurocysticercosis
References

References

  1. Zee CS, Go JL, Kim PE, DiGiorgio CM. Imaging of neurocysticercosis. Neuroimaging Clin N Am. May 2000;10(2):391-407. [Medline].

  2. Wallin MT, Kurtzke JF. Neurocysticercosis in the United States: review of an important emerging infection. Neurology. Nov 9 2004;63(9):1559-64. [Medline].

  3. Rosenfeld EA, Byrd SE, Shulman ST. Neurocysticercosis among children in Chicago. Clin Infect Dis. Aug 1996;23(2):262-8. [Medline].

  4. Almeida CR, Ojopi EP, Nunes CM, et al. Taenia solium DNA is present in the cerebrospinal fluid of neurocysticercosis patients and can be used for diagnosis. Eur Arch Psychiatry Clin Neurosci. Aug 2006;256(5):307-10. [Medline].

  5. Pradhan S, Kathuria MK, Gupta RK. Perilesional gliosis and seizure outcome: a study based on magnetization transfer magnetic resonance imaging in patients with neurocysticercosis. Ann Neurol. 2000;48:181-187. [Medline].

  6. Del Brutto, O. H.Roos, K. L.Coffey, C. S.Garcia, H. H. Meta-analysis: Cysticidal drugs for neurocysticercosis: albendazole and praziquantel. Ann Intern Med. 2006;145:43-51. [Medline].

  7. Vazquez V, Sotelo J. The course of seizures after treatment for cerebral cysticercosis. N Engl J Med. Sep 3 1992;327(10):696-701. [Medline].

  8. Talukdar B, Saxena A, Popli VK. Neurocysticercosis in children: clinical characteristics and outcome. Ann Trop Paediatr. Dec 2002;22(4):333-9. [Medline].

  9. Garcia HH, Pretell EJ, Gilman RH. A trial of antiparasitic treatment to reduce the rate of seizures due to cerebral cysticercosis. N Engl J Med. Jan 15 2004;350(3):249-58. [Medline].

  10. Del Brutto OH, Castillo PR, Mena IX, Freire AX. Neurocysticercosis among patients with cerebral gliomas. Arch Neurol. Sep 1997;54(9):1125-8. [Medline].

  11. Del Brutto OH, Rajshekhar V, White AC. Proposed diagnostic criteria for neurocysticercosis. Neurology. Jul 24 2001;57(2):177-83. [Medline].

  12. Fleury A, Hernandez M, Avila M, et al. Detection of HP10 antigen in serum for diagnosis and follow-up of subarachnoidal and intraventricular human neurocysticercosis. J Neurol Neurosurg Psychiatry. Sep 2007;78(9):970-4. [Medline].

  13. Leonard R, Adickes ED, Brumback RA. Neurocysticercosis. J Child Neurol. Jul 2006;21(7):589-90. [Medline].

  14. Li J, Zhang WB, Wilson M, et al. A novel recombinant antigen for immunodiagnosis of human cystic echinococcosis. J Infect Dis. Dec 15 2003;188(12):1952-61. [Medline].

  15. Marconi VC, Garcia HH, Katz JT. Neurocysticercosis. Curr Infect Dis Rep. Jun 2006;8(4):293-300. [Medline].

  16. Motamedi G. Baylor Neurology Case of the Month #10. Baylor College of Medicine. Available at http://www.bcm.tmc.edu/neurol/challeng/pat10/summary.html. Accessed 1999.

  17. Nash TE, Singh G, White AC, et al. Treatment of neurocysticercosis: current status and future research needs. Neurology. Oct 10 2006;67(7):1120-7. [Medline].

  18. Pineda T, Eckstein C, Diethelm G, Cure J. Neurocysticercosis. Headache. May 2007;47(5):717-8. [Medline].

  19. Ruiz-Garcia M, Gonzalez-Astiazaran A, Rueda-Franco F. Neurocysticercosis in children. Clinical experience in 122 patients. Childs Nerv Syst. Nov-Dec 1997;13(11-12):608-12. [Medline].

  20. Serpa JA, Yancey LS, White AC Jr. Advances in the diagnosis and management of neurocysticercosis. Expert Rev Anti Infect Ther. Dec 2006;4(6):1051-61. [Medline].

  21. Shandera WX, Kass JS. Neurocysticercosis: current knowledge and advances. Curr Neurol Neurosci Rep. Nov 2006;6(6):453-9. [Medline].

  22. Singhi P, Dayal D, Khandelwal N. One week versus four weeks of albendazole therapy for neurocysticercosis in children: a randomized, placebo-controlled double blind trial. Pediatr Infect Dis J. Mar 2003;22(3):268-72. [Medline].

  23. Singhi P, Singhi S. Neurocysticercosis in children. J Child Neurol. Jul 2004;19(7):482-92. [Medline].

  24. St. Geme JW 3d, Maldonado YA, Enzmann D, Hotez PJ, et al. Consensus: diagnosis and management of neurocysticercosis in children. Pediatr Infect Dis J. Jun 1993;12(6):455-61. [Medline].

  25. Swaiman KF. Cysticercosis. In: Pediatric Neurology: Principles and Practice. Vol 1. 2nd ed. St. Louis, Mo: Mosby; 1994:707-8.

Further Reading

Keywords

cysticercosis, taeniasis, tapeworm diseases, Taenia solium, T solium, Taenia saginata, T saginata, Cysticercus cellulosae, C cellulosae, parasite, parasitic infection, tapeworm, tapeworm infection, larval infection

Contributor Information and Disclosures

Author

Vinod K Dhawan, MD, FACP, FRCP(C), Professor, Department of Clinical Medicine, University of California at Los Angeles; Professor of Medicine, Charles R Drew University of Medicine and Science; Chief, Division of Infectious Diseases, MLK-Harbor Hospital
Vinod K Dhawan, MD, FACP, FRCP(C) is a member of the following medical societies: American College of Physicians, American Society for Microbiology, American Society of Tropical Medicine and Hygiene, Infectious Diseases Society of America, and Royal College of Physicians and Surgeons of Canada
Disclosure: Pfizer Inc None None

Coauthor(s)

Eric HW Kossoff, MD, Assistant Professor, Departments of Pediatrics and Neurology, Associate Director of Pediatric Neurology Residency Program, Johns Hopkins School of Medicine
Eric HW Kossoff, MD is a member of the following medical societies: American Academy of Neurology, American Academy of Pediatrics, American Epilepsy Society, and Child Neurology Society
Disclosure: Nothing to disclose.

Medical Editor

Ashir Kumar, MBBS, MD, FAAP, Professor, Department of Pediatrics and Human Development, College of Human Medicine, Michigan State University; Consulting Staff, Department of Pediatrics, EW Sparrow Hospital
Ashir Kumar, MBBS, MD, FAAP is a member of the following medical societies: American Academy of Pediatrics, American Association of Physicians of Indian Origin, American Federation for Clinical Research, American Society for Microbiology, Infectious Diseases Society of America, and Pediatric Infectious Diseases Society
Disclosure: Nothing to disclose.

Pharmacy Editor

Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine.com, Inc
Disclosure: Nothing to disclose.

Managing Editor

Leslie L Barton, MD, Professor, Program Director, Department of Pediatrics, University of Arizona School of Medicine
Leslie L Barton, MD is a member of the following medical societies: American Academy of Pediatrics, Association of Pediatric Program Directors, Infectious Diseases Society of America, and Pediatric Infectious Diseases Society
Disclosure: Nothing to disclose.

CME Editor

Robert W Tolan Jr, MD, Chief of Allergy, Immunology and Infectious Diseases, The Children's Hospital at Saint Peter's University Hospital; Clinical Associate Professor of Pediatrics, Drexel University College of Medicine
Robert W Tolan Jr, MD is a member of the following medical societies: American Academy of Pediatrics, American Medical Association, American Society for Microbiology, American Society of Tropical Medicine and Hygiene, Infectious Diseases Society of America, Pediatric Infectious Diseases Society, Phi Beta Kappa, and Physicians for Social Responsibility
Disclosure: GlaxoSmithKline Honoraria Speaking and teaching; MedImmune Honoraria Consulting; MedImmune Honoraria Speaking and teaching; Merck Honoraria Speaking and teaching; Novartis Honoraria Speaking and teaching; sanofi pasteur Grant/research funds Unrestricted research grant; sanofi pasteur  Consulting; sanofi pasteur Honoraria Speaking and teaching; Tap Honoraria Speaking and teaching

Chief Editor

Russell W Steele, MD, Professor and Vice Chairman, Department of Pediatrics, Head, Division of Infectious Diseases, Louisiana State University Health Sciences Center
Russell W Steele, MD is a member of the following medical societies: American Academy of Pediatrics, American Association of Immunologists, American Pediatric Society, American Society for Microbiology, Infectious Diseases Society of America, Louisiana State Medical Society, Pediatric Infectious Diseases Society, Society for Pediatric Research, and Southern Medical Association
Disclosure: None None None

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.